CNTNAP1 and chronic inflammatory demyelinating polyradiculoneuropathy: In CIDP with predominantly IgG4 autoantibodies against the paranodal components neurofascin-155 (NF155), contactin-1, or contactin-associated protein 1 (Caspr1), rituximab has been applied to corticosteroid and IVIg-refractory cases (249).